Search Results 301-310 of 15267 for TNF

1. A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) - Mayo Clinic

   ... TNF-α agents) within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressive medication during study treatment ...

2. A Study to Evaluate Budesonide in Patients with Immune Mediated Enteropathies - Mayo Clinic

   Other immune mediating medications; for example, but not limited to, azathioprine, 6-mercaptopurine, cyclosporine, methotrexate, anti-TNF monoclonal ...

3. A Study to Evaluate the Safety and Effectiveness of IFX-1 in Add-on to Standard of Care in Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - Mayo Clinic

   Received CD20 inhibitor, anti-tumor necrosis factor treatment, abatacept, alemtuzumab, any other experimental or biological therapy, intravenous ...

4. A Study of the Safety and Effectiveness of GS-5745 in Adults with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

   Immunomodulators; Tumor necrosis factor-alpha (TNFα) antagonists; Vedolizumab. Exclusion Criteria. Diagnosis of Crohn's disease or indeterminate colitis ...

5. A Study to Assess Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease - Mayo Clinic

   ... TNF-α antagonist or vedolizumab or ustekinumab, or having documented intolerance. Women of childbearing potential (WCBP) must have negative serum pregnancy ...

6. A Study to Evaluate the Effectiveness of a Dexamethasone Eluting Slim Modiolar Electrode in the Reduction of Fibrosis in a Newly Implanted Adult Population with Bilateral, Post-Linguistic, Moderate to Profound Sensorineural Hearing Loss - Mayo Clinic

   A Study to Evaluate the Effectiveness of a Dexamethasone Eluting Slim Modiolar Electrode in the Reduction of Fibrosis in a Newly Implanted Adult Population ...

7. Olaparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer - Mayo Clinic

   ... tumor necrosis factor [anti-TNF] agents) is allowed, provided the following is met: minimum of 2 weeks prior to Cycle 1, Day 1. Patients who have received ...

8. A Study of HFB200301 in Adult Patients With Advanced Solid Tumors - Mayo Clinic

   - Prior exposure to agents targeting the Tumor Necrosis Factor Receptor type 2 (TNFR2) receptor - Active autoimmune disease requiring systemic treatment in ...

9. Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma - Mayo Clinic

   ... TNF-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study ...

10. Publications - Paschalis Vergidis, M.D., M.S. - Mayo Clinic

    Histoplasmosis complicating tumor necrosis factor-alpha blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis. 2015 Aug 1; 61 (3):409-17 ...